ChristianaCare’s Gene Editing Institute has secured a prominent place on The Scientist’s Top 10 Innovations list for 2024, ...

In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

This illustration compares various gene editing technologies, including meganucleases, zinc finger nucleases, TALENs, and CRISPR/Cas9, along with their relative feasibility and mechanisms of DNA ...

A ruthenium catalyst facilitated the polymerization, or polymer addition. Industrial firms have used this catalyst to make ...

In July 2023, Sanofi expanded an existing partnership with Scribe Therapeutics to use its CRISPR-based gene-editing technology to develop both in vivo and ex vivo cancer cell therapies.

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease ...

CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.